235 related articles for article (PubMed ID: 30745156)
1. Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding).
Albin N; Chassagnol F; Bergmann JF; ;
Therapie; 2019 Feb; 74(1):103-117. PubMed ID: 30745156
[TBL] [Abstract][Full Text] [Related]
2. Telemedicine: what framework, what levels of proof, implementation rules.
Zannad F; Maugendre P; Audry A; ; Avril C; Blaise L; Blin O; Burnel P; Falise-Mirat B; Girault D; Giri I; Goehrs JM; Lassale C; Le Meur R; Leurent P; Ratignier-Carbonneil C; Rossignol P; Satonnet E; Simon P; Treluyer L
Therapie; 2014; 69(4):339-54. PubMed ID: 25230356
[TBL] [Abstract][Full Text] [Related]
3. European Court of Justice. ECJ 2014/6 Octapharma France SAS v. Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Ministère des Affaires Sociales et de la Santé, 13 March 2014 (C-512/12).
Baeyens A; Goffin T
Eur J Health Law; 2014 Jun; 21(3):317-21. PubMed ID: 25065041
[No Abstract] [Full Text] [Related]
4. The European "clinical trial" regulation; relationship with the Jardé Act: a Giens workshop.
Lemaire F; Marchenay B; Chassany O; ; Barthélémy P; Bouzzagou M; Comet D; Delval C; Dubray C; Fouret C; Frija-Orvoen E; Gambotti L; Lamarque V; d'Orsay G; Plattner V; Sibenaler C; Roux J; Thoby F
Therapie; 2015; 70(1):21-36. PubMed ID: 25679191
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Albin N; Chassagnol F; Bergmann JF; ;
Therapie; 2019 Feb; 74(1):87-101. PubMed ID: 30612729
[No Abstract] [Full Text] [Related]
6. The French Cochlear Implant Registry (EPIIC): General indicators.
Gauvrit F; Risoud M; Aubry K; Bordure P; Bozorg-Grayeli A; Deguine O; Eyermann C; Franco-Vidal V; Godey B; Guevara N; Karkas A; Klopp N; Labrousse M; Lebreton JP; Lerosey Y; Lescanne E; Loundon N; Marianowski R; Merklen F; Mezouaghi K; Mom T; Moreau S; Mosnier I; Noël-Petroff N; Parietti C; Piller P; Poncet C; Radafy E; Roman S; Roux-Vaillard S; Schmerber S; Tavernier L; Truy E; Vincent C
Eur Ann Otorhinolaryngol Head Neck Dis; 2020 Sep; 137 Suppl 1():S5-S9. PubMed ID: 32891589
[TBL] [Abstract][Full Text] [Related]
7. [From psychoactive medicines to addictovigilance in French Public Health Code (1990-2017)].
Baumevieille M; Perri-Plandé J; Miremont-Salamé G; Daveluy A; Haramburu F
Therapie; 2019 Jun; 74(3):375-382. PubMed ID: 30193805
[TBL] [Abstract][Full Text] [Related]
8. [Market access agreements: Definition and features. Could MAA be defined as a solution for immunotherapy funding by French health system?].
Ceyrac T; Corny J; Raybaut C; Degrassat-Théas A; Paubel P
Ann Pharm Fr; 2018 Jul; 76(4):265-272. PubMed ID: 29573790
[TBL] [Abstract][Full Text] [Related]
9. [Access to medicines in France].
Bouvenot G; Bouvenot J
Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
[TBL] [Abstract][Full Text] [Related]
10. La haute fiabilité en soins de santé: la création d'une culture et d'une mentalité favorisant la sécurité des patients.
Cochrane BS; Hagins M; Picciano G; King JA; Marshall DA; Nelson B; Deao C
Healthc Manage Forum; 2017 Mar; 30(2):69-78. PubMed ID: 28929891
[TBL] [Abstract][Full Text] [Related]
11. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?
Doré J; Multon MC; Béhier JM;
Therapie; 2017 Feb; 72(1):21-38. PubMed ID: 28131442
[TBL] [Abstract][Full Text] [Related]
12. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review].
Munch G; Godart N
Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720
[TBL] [Abstract][Full Text] [Related]
13. [Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities!].
Jonville-Bera AP; Gautier S; Micallef J; Massy N; Atzenhoffer M; Drici MD; Grandvuillemin A;
Therapie; 2023; 78(5):477-488. PubMed ID: 36890032
[TBL] [Abstract][Full Text] [Related]
14. [Immunization: process of elaborating guidelines and their evolution in France].
Floret D
Ann Pharm Fr; 2009 May; 67(3):219-23. PubMed ID: 19446673
[TBL] [Abstract][Full Text] [Related]
15. [Acute cough in infants: impact on families and pharmacists of contraindications of the Agence nationale de sécurité du médicament et des produits de santé (ANSM)].
Alauzet F; Blanc S; Montaudié I; Piccini-Bailly C; Berlioz-Baudoin M; Bégassat M; Albertini M; Giovannini-Chami L
Arch Pediatr; 2014 May; 21(5):469-75. PubMed ID: 24726669
[TBL] [Abstract][Full Text] [Related]
16. Collaboration Between Health-Care Professionals, Patients, and National Competent Authorities Is Crucial for Prevention of Health Risks Linked to the Inappropriate Use of Drugs: A Position Paper of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé).
Vignot S; Daynes P; Bacon T; Vial T; Montagne O; Albin N; Emmerich J; Ratignier-Carbonneil C; Martin D; Maison P
Front Pharmacol; 2021; 12():635841. PubMed ID: 33995037
[No Abstract] [Full Text] [Related]
17. [The congress of the French Society of Pharmacology and Therapeutics celebrate in Nancy, 20 April 2016, 40 years of French Regional Pharmacovigilance Centres!].
Jonville-Béra AP; Mallaret M; Sgro C;
Therapie; 2016 Sep; 71(4):351-4. PubMed ID: 27296805
[TBL] [Abstract][Full Text] [Related]
18. Information sheets and informed consent forms for clinical study participants: towards standardised recommendations?
Chassany O; Bernard-Harlaut M; Guy G; Billon N
Therapie; 2009; 64(3):161-86. PubMed ID: 19671429
[TBL] [Abstract][Full Text] [Related]
19. Taking Account of Gender Differences When Designing Interventions in Occupational Health? Lessons from a Study of the "Healthy Enterprise" Standard in Québec: Les différences de genre sont-elles prises en compte lors de la conception des interventions de prévention en santé au travail? Résultats d une étude sur la norme "Entreprises en Santé" dans les entreprises au Québec.
Sultan-Taïeb H; St-Hilaire F; Lefebvre R; Biron C; Vézina M; Brisson C
New Solut; 2017 Nov; 27(3):361-381. PubMed ID: 28835173
[TBL] [Abstract][Full Text] [Related]
20. Evaluation d'impact sur la santé et évaluation d'impact sur l'équité en santé : éventail de pratiques et questions de recherche.
Villeval M; Bidault E; Lang T;
Glob Health Promot; 2016 Sep; 23(3):86-94. PubMed ID: 25833939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
